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Abstract 
By any measure, transdermal drug delivery (TDD) is a successful controlled release 
technology.  Over the last 30+ years, a steady flux of transdermal products have received 
regulatory approval and reached the market.  For the right compounds, TDD is an effective 
and preferred route of administration; for others, delivery across the skin makes no sense at 
all.  Currently, the “rules” that govern (passive) TDD feasibility are clearly understood, and 
research activity is focused on novel approaches that strive to subvert skin’s excellent barrier 
function, and broaden the range of active species amenable to percutaneous administration. 
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Introduction 
Prior to 1980, transdermal drug delivery (TDD) was limited to very few compounds (including 
nitroglycerin and estradiol) formulated in relatively simple ointments and gels.  The latter, 
conventional vehicles were inelegant, inefficient and suffered from poor control of both the 
quantity of drug applied and the area of skin exposed.  The outcome of this less than ideal 
situation was significant variability in the extent and duration of drug effect. 
The field was therefore primed for the concept, pioneered in large part by the Alza 
Corporation in Palo Alto, California, of a transdermal patch in which system design and 
explicit control of surface area were combined to create a technology capable of passive 
drug delivery to the systemic circulation at a predetermined rate [1]. 
Consequently, a clear, perceived advantage of TDD was the provision of a prolonged period 
of administration, during which drug levels would be maintained within the therapeutic 
window, offering thereby a extended duration of action and, for compounds of short 
biological half-life, a reduced frequency of dosing.  It was further argued, not unreasonably, 
that achieving these aims would lower variability, both within and between patients and 
substantially improve, as a result, compliance and adherence with drug use [1-3]. 
Two further key benefits were also immediately apparent.  The first addressed an important 
problem for a number of (up until the advent of TDD) orally administered drugs; specifically, 
those subject to a large, pre-systemic first-pass effect.  Such compounds typically have very 
low (or even non-existent, in some cases) oral bioavailability, particularly inconvenient 
dosing regimens, and significant incidences of adverse effects, often the result of the high 
levels of metabolite(s) formed on their first passage through the liver.  In contrast, by 
administering such drugs transdermally, the classic first-pass effect is avoided and these 
major drawbacks are circumvented [1-4]. 
The second is self-evidently practical in nature: in situations where drug input is no longer 
desirable (due, for instance, to an important change in a patient’s status), transdermal 
administration can be stopped by removal of the patch.  Apart from an intravenous infusion, 
there is no other route of drug delivery for which this is instantaneously possible1 [4, 5]. 
Taken together, the potential benefits of TDD led, in the early days, to some frankly 
‘hallucinogenic’ claims about the future breadth of application of the administration route.  
However, it did not take long before reality reasserted its grip on the field and it became 
clear that the systemic delivery of drugs across the skin would be subject to a number of 
limitations.  Most importantly, given that the skin’s principal function is to act as a protective 
barrier, and that the rate of molecular transport through (in particular) the outermost layer, 
the stratum corneum, is highly constrained and very slow, it follows that TDD is suitable only 
                                                        
1
 Of course, drug, which has been released from the patch and is diffusing across the skin, but has not yet been 
‘resorbed’ into the blood circulation, will ultimately be absorbed (albeit at a reduced rate as the driving 
concentration gradient will have been removed). 
for very potent drugs [1].  Indeed, the daily dose of those compounds, which have reached 
the market, is measured typically in terms of a few milligrams (Table 1). 
Furthermore, given the relationship between molecular properties and skin permeability, 
there have emerged certain (Lipinski-like) ‘rules’ that a drug must satisfy, in addition to 
potent pharmacological activity, to become a feasible candidate for TDD [6]; specifically: (a) 
modest molecular weight (MW < 400 to 500 Da), (b) a balanced lipophilicity (log{octanol-
water partition coefficient}, log P, ideally around 2 to 3), and (c) a measurable solubility both 
in oil and in water (given that TDD requires both breaching the lipophilic stratum corneum 
and resorption into the aqueous central compartment of the systemic circulation). 
The combination of the right physicochemical properties to enable skin penetration, and the 
ability to elicit the desired therapeutic effect at very low concentration, means that TDD can 
be achieved from a patch of reasonable size: currently, there are few transdermal systems in 
use of area greater than 50 cm2 (about the size of a credit card).  Should either skin 
permeability or pharmacological potency be insufficient, then TDD becomes impossible 
without an impracticably large patch [1, 3].  Testosterone, for example, has walked this fine 
line with the result that the present approach of choice to deliver this compound is a gel 
formulation, which can be applied over a larger surface area2. 
A further limitation of considerable relevance is skin tolerability.  Because skin sensitivity 
varies widely among individuals, all transdermal systems on the market include skin 
irritation in their list of adverse effects; indeed, merely occluding the skin with a patch can 
be enough to cause obvious reddening of the application site [1].  However, some drugs are 
themselves irritating and the careful, early testing of skin irritation (and sensitisation) due to 
the active agent is a key component of TDD development.  For the moment, while there are 
clues to the chemical structure – skin sensitisation relationship, it remains difficult to predict 
a priori whether a drug will provoke a degree of irritation sufficient to cause cessation of 
further development: in vivo evaluation is essential.  It is almost certainly true that many 
transdermal projects have fallen at the skin tolerability hurdle. 
                                                        
2
 In the case of testosterone, the therapeutic window is relatively large, meaning that the inherent inaccuracy 
in dosing a conventional formulation over a less than precisely defined surface area of skin is acceptable. 
Table 1: Daily dose ranges and selected physicochemical and pharmacokinetic properties of 
currently approved transdermally delivered drugs.  
 
Drug (year of 
approval) 
Dose/day 
(mg) 
MW 
(Da) 
log Pa Cl (L/hr) t½ (hr)
b F (%)c Cp,eff 
(ng/mL)e 
Scopolamine (1979) 0.3 303 0.98 672 2.9 27 0.04 
Glyceryl trinitrate 
(1981) 
2.4 - 15 227 1.62 966 0.04 < 1 0.1 - 5 
Clonidine (1984) 0.1 - 0.3 230 2.42 ± 0.52  13 6 - 20 95 0.2 - 2.0 
Estradiol (1986) 0.025 - 0.100 272 4.01 615 - 790 0.05 3-5 0.04 - 0.06 
Fentanyl (1990) 0.288 - 2.400 337 4.05 27 - 75 3 - 12 32 1.0 
Nicotine (1991) 7 - 21 162 1.17 78 2 30 10 - 30 
Testosterone (1993) 0.3 - 5  288 3.32  0.17 - 1.7 < 1 10 - 100 
Estradiol & 
Norethisterone Acetate 
(1998) 
0.025 - 0.050 
0.125 - 0.250 
272  
340 
4.01            
3.99 
 2 - 3       
6 – 8
d
 
3 - 5  
64 
0.04 - 0.07 
0.8 - 1.1 
Norelgestromin & 
Ethinyl Estradiol (2001) 
0.2                 
0.034 
327  
296 
3.90 ± 0.47 
3.67 
 28       
17
d
 
40 0.8           
0.05 
Estradiol & 
Levonorgestrel (2003) 
0.050            
0.007 - 0.015 
272  
312 
4.01            
3.72 ± 0.49 
 3         
28
d
 
3 - 5   0.03 - 0.05 
0.1 - 0.2 
Oxybutynin (2003) 3.9 357 4.02 ± 0.52   2 6 1.0 - 5.0 
Selegeline (2006) 6 - 12 187 2.90 84 10 10 2.0 - 3.0 
Methylphenidate 
(2006) 
26 - 80 233 2.15 ± 0.42  20 2 - 3 5 - 20 5.0 - 25 
Rotigotine (2007) 1 - 3 315 4.58 ± 0.72  600 5 – 7
d 
n/a ~1.0 
Rivastigmine (2007) 4.6 - 9.5 250 2.34 ± 0.16  108 1.5 40 ~10 
Granisetron (2008) 3.1 312 2.55 ± 0.28 33-76 
healthy 
15-34 
patients 
4 – 6 
healthy 
9-12 
patients 
60 0.7 - 9.5 
Buprenorphine (2010) 0.12 - 1.68 468 4.98 55 22 – 36
d
 n/a 0.1 - 0.4 
aLog{octanol-water partition coefficient (P)}: either experimental or calculated (mean ± SD) values. 
bTerminal half-life post-oral or IV dosing. 
cOral bioavailability. 
dTerminal half-life following transdermal delivery. 
ePharmacologically effective plasma concentration. 
 
Current state-of-the-art 
The presently approved drugs in the U.S.A. and Europe for passive transdermal delivery are 
listed in Table 1 (in the chronological order of approval by the Food & Drug Administration).  
The limited number of compounds seen in this list reflects the difficulty of meeting the dual 
challenge of high pharmacological potency and skin permeability necessary for successful 
TDD.  Over the last 30+ years, therefore, approval for a new compound to be administered 
as a transdermal patch has occurred approximately once every two years. 
Nevertheless, TDD today represents annually a multi-billion (US) dollar market and a true 
controlled drug release success story [7].  It’s fair to say that, apart from the field of oral 
administration, TDD’s ‘return on investment’, from the standpoint of the translation of 
research to clinical application, is second to none.  Indeed, transdermal fentanyl, for at least 
the last 5 years, may be considered a pharmaceutical “blockbuster”, with annual sales 
exceeding US$ 1Billion!  The transdermal patch concept is well-known and accepted by the 
general public, and it is now possible to purchase nicotine patches over-the-counter from a 
pharmacy or supermarket. 
Further examination of Table 1 reveals that all of drugs approved for transdermal delivery, 
with the single exception of rotigotine, were previously available to patients by another 
route of administration (such as oral, sublingual, injection, etc.).  Rotigotine was the first 
and, for the moment, the only new chemical entity to be developed and approved by the 
regulatory authorities specifically for transdermal delivery [8].  It remains to be seen 
whether this bold approach becomes a seriously considered alternative by the 
pharmaceutical industry for potent development candidates deemed unsuitable for oral 
administration because of metabolic (first-pass effect) sensitivity. 
Typically, the strategy is to formulate the drug in a suitable, adhesive polymer matrix, or in 
two such layers (Figure 1), at a loading close to saturation, thereby providing the maximum 
driving force for passive diffusion across the skin (see following section) [4].  Variation of the 
patch area can then be used to titrate the dose delivered in a direct proportion (Figure 2), or 
to transfer a degree of drug input rate control from the skin to the delivery system [9]. 
Figure 1: Schematic diagrams of typical “matrix” passive transdermal drug delivery systems.  
For clarity, the release liner, which contacts the drug-in-adhesive layer, and which 
is removed before patch application, is not shown. 
 
 
 
 
Figure 2: Steady-state plasma concentrations of three drugs after transdermal delivery as a 
function of patch area (redrawn from ref [4]). 
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Transdermal drug delivery – feasibility and control 
Assuming that a suitably potent drug candidate has been identified for which a convenient 
oral dosing regimen proves impossible (e.g., due to high first-pass effect, short biological 
half-life, etc.), then the feasibility of transdermal delivery requires an assessment of the 
molecule’s skin penetrability.  A default starting position is to estimate the compound’s 
maximum flux across the skin (Jmax, typically in units of μg/cm
2/hr)) and to evaluate whether 
this value is sufficient to satisfy the steady-state, “rate in = rate out” equation below where 
Q (mg) is the anticipated daily dose and with A (cm2), the patch area, being no greater than 
50 cm2: 
1000
24( )´Q = A´ Jmax          (Eq. 1) 
Equation (1) can also be written, of course, in terms of the drug’s systemic clearance (Cl in 
L/hr) and effective steady-state plasma concentration (Cp,eff in μg/L); i.e., Cl×Cp,eff = A×Jmax 
[10]. 
The maximum steady-state flux across the skin is given by Fick’s 1st law of diffusion 
Jmax =
D
h( )´KSC/v ´Cv,sat = kp,v ´Cv,sat      (Eq. 2) 
where D is the compound’s diffusivity across (most typically) the stratum corneum (SC), h is 
the diffusion path-length through the barrier, KSC/v is the drug’s partition coefficient between 
the SC and the vehicle in which it is applied, and Cv,sat is its saturation solubility in the 
vehicle.  The permeability coefficient of the drug from the vehicle (kp,v, which has units of 
velocity, e.g., cm/hr) is a convenient shorthand that brings together three parameters that 
are difficult to uniquely determine by experiment. 
For TDD, the vehicle is most usually a patch (e.g., like those in Figure 1) and neither kp,v nor 
Cv,sat are routinely available.  However, at least in theory, Equation (2) should be valid for any 
vehicle, which does not alter the SC barrier, or change the drug’s solubility therein [11].  
Assuming that water satisfies these criteria, the corresponding permeability coefficient (kp,w) 
and aqueous solubility (Cw,sat) can then be used to estimate Jmax using Equation (2).  While 
water solubilities are typically measured experimentally in drug development, or can be 
derived from established algorithms, skin permeability coefficients from water may be 
accessed from Franz-type diffusion cell studies or predicted (in units of cm/hr) from the 
empirical relationship derived by Potts & Guy [12]: 
log kp,w = -2.7 + 0.71×log P – 0.0061×MW      (Eq. 3) 
(where P is the drug’s octanol-water partition coefficient (again, typically known or easily 
calculated) and MW is its molecular weight) and corrected for the contribution of the 
underlying viable skin for more lipophilic compounds by Cleek & Bunge [13]: 
kp,w
corr =
kp.w
1+
kp,w ´ MW
2.6
æ
è
ç
ç
ö
ø
÷
÷
        (Eq. 4) 
This approach has been adopted for the 18 drugs approved for transdermal delivery (and 
identified in Table 1) and the results are presented in Table 2.  Lipophilicities  (i.e., log P 
values) and water solubilities were either obtained from readily accessible databases [14, 
15], or were estimated using freely available algorithms [14, 15].  In general, while the latter 
produced estimates of log P with little variability, the calculated values of Csat,w were less 
consistent, especially for drugs of poor aqueous solubility. 
It is immediately apparent that the ability of approved transdermal drugs to penetrate the 
skin varies widely from the extremely permeable nicotine to compounds, such as 
buprenorphine and the progestins, which have very low predicted fluxes.  Given, as 
mentioned above, that the ‘default’ position in developing a transdermal patch is to create a 
polymer matrix, which is saturated with a sufficient payload of the drug to ensure delivery 
for the duration of application, it is informative to compare the estimated Jmax values in 
Table 2 with the labelled in vivo delivery rates of the products on the market.  This 
information is collected in Table 3, and the ratios of the clinical input rates to the estimated 
maximum fluxes is illustrated graphically in Figure 3. 
If all transdermal systems were formulated to provide the maximum thermodynamic driving 
force for passive diffusion across the skin, the ratios in Figure 3 should all be equal to 1.  
Given the inherent uncertainty in the parameters used in Equation (2) to determine Jmax, it 
has been proposed [16] that ratios falling within an order of magnitude of this ideal value 
are reflective of patches in which the drug’s activity is at or close to optimal. 
In those cases where the in vivo delivery rate falls well below Jmax, for example with nicotine, 
it is clear that the transdermal systems have been formulated with a lower loading of the 
drug (i.e., below the saturation concentration) and that they have assumed a degree of rate 
control so as to prevent a potentially excessive exposure of the patient to the active 
compound.  Nicotine, self-evidently, permeates the skin very quickly, to an extent which is 
far greater than necessary for its use in smoking cessation patches. 
The situations in which the achieved delivery rates exceed Jmax significantly can, more often 
than not, be attributed to the presence in the patch formulations of excipients recognised to 
be skin penetration enhancers, either through perturbation of SC lipid organisation thereby 
increasing drug diffusivity, or via their ability to promote drug solubilisation within the 
barrier and provide a steeper concentration gradient to drive the flux to a higher level.  
Examples in the former category include MinitranS (glyceryl trinitrate), which contains 
glycerol monolaurate and ethyl oleate, and Andropatch (testosterone), which includes 
glycerol monooleate, methyl laurate and ethanol.  In the latter group, the effect may be 
achieved somewhat indirectly in the manufacturing process where the drug is typically and 
initially dissolved with a polymeric adhesive in an organic solvent(s).  Once cast on the 
release liner or backing film, a controlled drying process evaporates solvent, resulting, in 
certain cases, to supersaturation of drug within the patch.  If this metastable state persists 
until application to the skin, then a concomitant supersaturation of the active agent can be 
produced in the SC and a greater-than-anticipated flux will result.  Neupro (rotigotine) 
adopts a different approach to improve drug solubility in the SC: incorporation into the 
patch of the excipient, povidone (or polyvinylpyrrolidone, PVP), causes water to be taken up 
from the skin into the delivery system, shifting the partition coefficient of the lipophilic drug 
more favourably towards the SC.  A similar strategy is used in other transdermal products 
(such as those containing buprenorphine and norethisterone acetate), sometimes in 
combination with an additional excipient that acts on the SC lipid organisation. 
Transdermal delivery has also benefitted from advances in adhesive science, an excellent 
illustration being the so-called DOT-MatrixTM (delivery-optimised thermodynamics) 
technology [17], which allows increased drug loading per unit quantity of adhesive and the 
use of a smaller patch area.  In a matrix patch based on the DOT technology, an acrylic 
adhesive, for example, is loaded with the drug and then dispersed into a silicone adhesive in 
which the active compound is less soluble.  The supply of drug from the ‘encapsulated’ 
acrylic “cells” maintains its thermodynamic activity in the silicone adhesive at the maximum 
level ensuring the most efficient delivery possible.  The technology is used in various patches 
at present, most impressively perhaps in the Daytrana (methylphenidate) system for the 
treatment of ADHD in children. 
Table 2: Predictions of the maximum fluxes of drugs currently approved for transdermal 
delivery in Europe and the USA. 
Drug MW (Da) log Pa ± SD
Cw,sat 
(mg/cm3)b
± SD log kp,w kp,w (cm/h)
c kp,w
corr 
(cm/h)d
Jmax 
(µg/cm2/h)e
Nicotine 162.2 1.17 1000 -2.843 1.44E-03 1.43E-03 1425
Selegilene 187.3 2.90 1.14 -1.765 1.72E-02 1.58E-02 18.0
Scopolamine 303.4 0.98 100 -3.825 1.50E-04 1.49E-04 14.9
Rivastigmine 250.3 2.34 0.16 3.37 1.18 -2.540 2.88E-03 2.83E-03 9.53
Clonidine 230.1 2.42 0.52 1.60 2.34 -2.362 4.34E-03 4.23E-03 6.77
Methylphenidate 233.3 2.15 0.42 1.14 1.04 -2.573 2.67E-03 2.63E-03 2.99
Fentanyl 336.5 4.05 0.20 -1.844 1.43E-02 1.30E-02 2.60
Glyceryl trinitrate 227.1 1.62 1.38 -2.912 1.22E-03 1.21E-03 1.67
Granisetron 312.4 2.55 0.28 0.61 0.81 -2.764 1.72E-03 1.70E-03 1.04
Oxybutynin 357.5 4.02 0.52 0.034 0.036 -1.991 1.02E-02 9.50E-03 0.32
Rotigotine 315.5 4.58 0.72 0.0091 0.0006 -1.341 4.56E-02 3.47E-02 0.32
Testosterone 288.4 3.32 0.023 -2.073 8.44E-03 8.00E-03 0.18
Ethinyl estradiol 296.4 3.67 0.011 -1.873 1.34E-02 1.23E-02 0.14
Estradiol 272.4 4.01 0.0039 -1.487 3.25E-02 2.70E-02 0.11
Buprenorphine 467.6 4.98 0.0067 0.0073 -1.970 1.07E-02 9.84E-03 0.07
Norethisterone acetate 340.5 3.99 0.0053 -1.910 1.23E-02 1.13E-02 0.06
Norelgestromin 327.5 3.90 0.47 0.0036 0.0019 -1.896 1.27E-02 1.17E-02 0.04
Levonorgestrel 312.5 3.72 0.49 0.0015 0.0014 -1.934 1.16E-02 1.08E-02 0.02  
aWhen available, experimental values are given; otherwise, the average of calculated estimates – in 
italics - are provided (with SD in the following column); see text for details. 
bWhen available, experimental values are given; otherwise, the average of calculated estimates – in 
italics - are provided (with SD in the following column); see text for details. 
cCalculated using Equation (3). 
dCalculated using Equation (4). 
eCalculated using Equation (2) using the values of kp,w
corr and Cw,sat in the Table. 
 
Table 3: Delivery rates and active areas of commercialised transdermal products and 
comparison of labelled in vivo input fluxes across the skin with the corresponding 
maximum values (Jmax) estimated theoretically.  
Product - Drug Delivery rate Active area 
(cm
2
) 
Jin vivo 
a 
μg/cm
2
/hr 
Jmax 
μg/cm
2
/hr 
Jin vivo/Jmax 
Transderm Scop - Scopolamine 1 mg/72 h
 
2.5 5.6 14.9 0.38 
Nitroderm TTS - GTN
b
 
Deponit TTS - GTN
b
 
MinitranS - GTN
b
 
5-15 mg/24 h
 
5, 10 mg/24 h
 
5 mg/24 h
 
10 - 30 
9, 18 
6.7 
20 
23 
31 
1.67 12 
14 
19 
Catapres-TTS - Clonidine 0.1 - 0.3 mg/24 h
 
3.5 - 10.5 1.2 6.77 0.18 
Dermestril/Alora - Estradiol 
Estradot/Vivelle-Dot - Estradiol 
Dermestril Septem - Estradiol 
Fem7 - Estradiol 
Menorest - Estradiol 
Estrapatch - Estradiol 
Esclim - Estradiol 
Climara - Estradiol 
Sequidot Phase I - Estradiol 
Fem7 Combi/Conti - Estradiol
c 
Climara Pro - Estradiol
c 
Sequidot Phase II - Estradiol
c 
Estragest - Estradiol
c 
Combipatch - Estradiol
c
 
25-100 μg/24 h
 
25-100 μg/24 h 
25 μg/24 h 
50-100 μg/24 h 
37.5-100 μg/24 h 
40-80 μg/24 h 
25-100 μg/24 h 
25-100 μg/24 h 
50 μg/24 h 
50 μg/24 h 
45 μg/24 h 
50 μg/24 h 
25 μg/24 h 
50 μg/24 h
 
9 - 36 
2.5 - 10 
11.25 
15 - 30 
11 - 29 
14.25 - 28.5 
11 - 44 
6.5 - 25 
5 
15 
22 
16 
10 
9 
0.12 
0.42 
0.09 
0.14 
0.14 
0.12 
0.09 
0.17 
0.42 
0.14 
0.09 
0.13 
0.10 
0.23 
0.11 1.1 
3.8 
0.84 
1.3 
1.3 
1.1 
0.86 
1.5 
3.8 
1.3 
0.77 
1.2 
0.95 
2.1 
Durogesic SMAT - Fentanyl 
Fentadolon - Fentanyl 
Matrifen - Fentanyl 
Fentalis Reservoir - Fentanyl 
12-100 μg/h 
25 μg/h 
25 μg/h 
25 μg/h 
25 - 42 
15 
8.4 
10 
2.4 
1.7 
3.0 
2.5 
2.60 0.92 
0.64 
1.1 
0.96 
Nicorette TX - Nicotine 
NiQuitin CLEAR - Nicotine 
Nicotinell/Habitrol - Nicotine 
10-25 mg/16 h
 
7-21 mg/24 h 
7-21 mg/24 h
 
9 - 22.5 
7 - 22 
10 - 30 
69 
42 
29 
1425 0.05 
0.03 
0.02 
Intrinsa - Testosterone 
Testopatch - Testosterone 
Testoderm TTS
d
 - Testosterone 
Andropatch - Testosterone 
0.3 mg/24 h 
1.2-2.4 mg/24 h 
5 mg/24 h 
2 mg/24 h 
28 
30 - 60 
60 
32 
0.45 
1.7 
3.5 
2.6 
0.18 2.5 
9.3 
19 
14 
Sequidot Phase II – Nor’acetate
e 
Estragest – Nor’acetate
e
 
Combipatch – Nor’acetate
e 
250 μg/24 h 
125 μg/24 h 
140 μg/24 h 
16 
10 
9 
0.65 
0.52 
0.65 
0.06 11 
8.7 
11 
Evra - Norelgestromin 203 μg/24 h 20 0.42 0.04 11 
Evra – Ethinyl estradiol 33.9 μg/24 h 20 0.07 0.14 0.50 
Fem7 Combi - Levonorgestrel 
Fem7 Conti - Levonorgestrel 
Climara Pro - Levonorgestrel 
10 μg/24 h 
7 μg/24 h 
15 μg/24 h 
15 
15 
22 
0.03 
0.02 
0.02 
0.02 1.4 
0.97 
0.95 
Kentera/Oxytrol - Oxybutynin 3.9 mg/24 h 39 4.2 0.32 13 
Emsam - Selegeline 6-12 mg/24 h 20 - 40 13 18 0.69 
Daytrana - Methylphenidate 1.1-3.3 mg/h 12.5 - 37.5 88 2.99 29 
Neupro - Rotigotine 1, 3 mg/24 h
 
5, 15 8.3 0.32 26 
Exelon - Rivastigmine 4.6, 9.5 mg/24 h
 
5, 10 38 9.53 4.0 
Sancuso - Granisetron 3.1 mg/24 h 52 2.5 1.04 2.4 
BuTrans/Norspan - Buprenorph
f 
5-20 μg/h 6.25 - 25 0.8 0.07 11 
Transtec Pro - Buprenorph
f
 35-70 µg/h 25 - 50 1.4 0.07 20 
aDeduced from the labelled delivery rate and active area of the patch. 
bGTN = glyceryl trinitrate. 
cEstradiol present in combination patches with either norethisterone acetate or levonorgestrel. 
dPatch is for application to the scrotum. 
eNor’acetate = norethisterone acetate. 
fBuprenorph = buprenorphine. 
 
Figure 3: Graphical illustration of the ratio of drug fluxes across the skin in vivo from 
marketed transdermal patches to theoretical estimates of the corresponding Jmax 
values. 
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Future perspectives for transdermal drug delivery 
Despite the important achievements of TDD over the past three decades or so, it remains an 
undeniable fact that the route of administration is limited to a relatively small subset of 
highly potent, low molecular weight and moderately lipophilic drugs.  Even with the 
enhancement of delivery possible via the use of different excipients, and combinations 
thereof, or by the clever ‘tweaking’ of the thermodynamics involved, only modest degrees of 
increased flux can be practically achieved.  As soon as one becomes more aggressive, for 
example by using more of an enhancer or more enhancers in a mixture, then unacceptable 
skin irritation (i.e., deal-breaking in terms of product development) is pretty much the 
inevitable result. 
Nonetheless, this has not deterred a cohort of determined transdermal scientists from 
continuing to carry the battle to the skin, attempting not only to persuade other small 
molecules of less attractive properties across the barrier, but also to explore more 
orthogonal ideas which may allow even macromolecular drugs to be administered 
transdermally. 
Inevitably, some of these battles have ended in resounding victories for the skin (and, in 
many cases, for common sense as well, it must be said), with forays involving liposomes, 
electroporation, the ‘gene gun’, to name but a few, ending up much like the Charge of the 
Light Brigade in 1854.  Others, in contrast, while yet to ‘deliver’ in a commercial sense, have 
shown more tenacity and have opened up new areas of research in which real advances 
have already been achieved. 
One of the most intensively studied approaches has been iontophoresis, and the use of the 
past tense reflects the fact that the level of activity is presently less than it was just before 
the new millennium.  Iontophoresis, of course, has been known and studied for over 100 
years and it remains, to all intents and purposes, the only ‘physical’ transdermal technology 
to have received regulatory approval and for which commercial products have been 
marketed3.  This mature technology is one for which an excellent mechanistic understanding 
has been defined and a more than reasonable safety profile exists.  It is recognised that the 
use of a small electric current to enhance TDD is not going to enable hundreds of drugs to 
become deliverable across the skin and, even though small proteins have been coaxed 
across the barrier with this approach [18], the scope for applying iontophoresis to the 
delivery of monoclonal antibodies, for example, is simply not going to happen.  
Nevertheless, products containing lidocaine, fentanyl and, most recently, sumatriptan have 
surmounted the regulatory hurdles and been commercialised.  Equally, transdermal 
iontophoresis formed the basis for the only noninvasive glucose monitor (the GlucoWatch 
BiographerTM) to have ever been approved by the U.S. FDA.  However, at the time of writing, 
                                                        
3
 In contrast, for example, to sonophoresis, which is yet to realise its original promise [Azagury A, Khoury L, 
Enden G, Kost J. Ultrasound mediated transdermal drug delivery. Adv Drug Deliv Rev. 2014. doi: 
10.1016/j.addr.2014.01.007]. 
the lidocaine, fentanyl and glucose monitoring systems are unavailable, having suffered a 
mix of commercial and technical setbacks, leading to their withdrawal from the market.   
It goes without saying that this has significantly undermined confidence in the future of 
iontophoresis as a viable transdermal technology and provides a real (and keenly observed) 
challenge for the sumatriptan product to overcome this difficult situation.  The experience 
with iontophoresis illustrates that the ‘marriage’ between a drug and its delivery system, 
particularly one that involves complex (and, almost always, more expensive) technology is 
never going to be an easy one.  There has to be an important unmet medical need, which is 
intractable to established, simpler (and, almost always, cheaper) approaches.  Had the three 
unsuccessful iontophoretic devices, which made it to the finishing line, worked absolutely as 
envisaged, then they may well have been of significant benefit and delivered a substantial 
financial return on investment.  In not meeting this bar, however, they rather quickly 
succumbed to a bad press that only highlighted their deficiencies while ignoring their very 
attractive attributes. 
What lies ahead for iontophoresis, then?  Clearly, the technology needs a commercial 
success and, as mentioned already, the launch of the newly approved sumatriptan system is 
a cause for great anticipation.  The field also needs to identify the best possible drug-disease 
combination to address with the technology.  One area, for example, in which extremely 
promising clinical data emerged a few years ago, involved the delivery of a peptide (MW = 
~1200 Daltons) used in fertility treatment.  The ability of short iontophoretic pulses to mimic 
the delivery of this compound that is typically given in a series of uncomfortable 
subcutaneous injections was quite remarkable (see Figure 4).  Finally, interest continues in 
the monitoring applications of iontophoresis, where glucose remains the Holy Grail of the 
field. 
As the highs and lows of iontophoresis played out on either side of the millennium, a new 
research effort became progressively more vocal and visible in the transdermal world, and 
the concept of “skin poration” moved squarely onto centre stage.  The almost heretical 
premise of this new wave was (i) to acknowledge the inconquerability of the SC (especially 
towards the delivery of biopharmaceuticals), and (ii) to devise means with which to 
circumvent the skin’s barrier.  The latter specifically involves creating new pathways through 
the SC using technologies that are minimally invasive, essentially painless and reversible. 
The skin permeabilisation methods are varied, with microneedles (of one sort or another) 
leading the way, followed by thermal and laser-assisted ablation. The number of 
publications addressing these technologies, especially microneedles, is growing 
exponentially and recent, authorative reviews are available in the literature [19-24].  In each 
approach, new, aqueous pathways are created across the outer few hundred microns (give 
or take) of the skin allowing the barrier function of the SC to be ‘short-circuited’ and relaxing 
two key limitations of passive transdermal delivery:  
(1)  The requirement for the drug to be lipophilic (to enable its partitioning into the 
SC) is lifted; indeed, delivery through ‘porated’ skin is best suited for molecules 
which have decent water solubility and, in the case of conventional, low MW 
compounds, use of the (frequently more stable) salt form of a drug is therefore 
preferred.  
(2)  The constraint of low molecular weight for TDD is removed; these technologies 
create openings in the skin which are measured in tens of microns, meaning that 
pretty much any biopharmaceutical (peptide, protein, antibody, vaccine, siRNA, 
oligonucleotide, DNA) can gain access following poration of the barrier. 
These widened boundary conditions, however, do not mean that TDD is suddenly possible 
for all conceivable drugs!  It remains the case that the route of administration is best suited 
to potent compounds, the dose requirements of which are modest; that is, it will still be 
impossible, for example, to deliver a drug requiring a dose of, say, 500 mg a day.  The 
practicality of such a challenge, in terms of delivery system design, is unclear and the skin’s 
reaction to the presence of the resulting large quantity of xenobiotic, which must flow 
through it per unit time, is unlikely to be a happy one. 
To illustrate the potential of, and the challenges facing, the skin poration field, we focus our 
attention on microneedles.  As stated above, this approach has been subject to the most 
intensive research effort and it is the most advanced in terms of progress with respect to 
clinical evaluation.  Although the idea of microneedles had been around for quite some time, 
the step change in microfabrication technology at the end of the 20th Century provided the 
trigger for the concomitant focus on applications in TDD.  Since then, enormous diversity in 
microneedle design and use, materials, fabrication methods, and potential therapeutic 
applications has been seen.  Table 4 attempts to capture this very broad spectrum of 
activity. 
In terms of progress towards clinical application of the microneedle technology, there are a 
number of human trials underway, with the majority focused on vaccine delivery.  As a first 
demonstration of the potential of the skin poration approach, vaccination is a very attractive 
option: the dose required is very low, administration is not needed on a continuous basis, 
the therapeutic window is relatively large, and the skin provides an excellent ‘amplification’ 
system for the desired immune response.  There would appear to be an excellent chance, 
therefore, that microneedle-based vaccinations will ultimately become generally available, 
both for immunisation against (e.g.) the influenza virus, but also to combat a range of 
diseases in sub-Saharan Africa, for example, where the delivery (in all senses of the word) of 
conventional vaccine formulations remains a significant challenge.  A more interesting, and 
less easily answered, question is what comes after vaccines?  Where is the obvious unmet 
medical need that microneedles (or indeed any of the poration approaches) can address 
better, more reliably and safer than a conventional needle-and-syringe? 
Figure 4: In vivo plasma concentration versus time profiles of a ~1200 Dalton peptide 
delivered systemically by either 3 subcutaneous injections or 3 x 5-minute pulses of 
transdermal iontophoresis (personal communication, Vyteris, Inc.). 
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Table 4: Summary of the microneedle technology field. 
Materials
a 
Silicon, metals, polymers, ceramics. 
Fabrication 
methods 
Lithography; wet and dry etching; laser cutting; micromolding. 
Mechanism Solid μneedles pre-treatment followed by drug formulation/patch application. 
Metal/polymer μneedles coated with drug-containing matrix which dissolves on 
insertion, releasing drug. 
Drug incorporated into polymer μneedles, which dissolve on insertion, releasing 
the active compound. 
Hollow μneedles through which liquid drug formulations can be infused. 
Medical 
applications 
Low MW drugs, including naltrexone, lidocaine, PDT applications. 
Biopharmaceuticals, including parathyroid hormone, insulin and other peptide 
and protein drugs. 
Vaccines, e.g., influenza, West Nile virus, HPV, etc. 
Sampling of interstitial fluid in viable skin for monitoring/diagnosis applications. 
Practical issues Sharpness, length, insertion force, velocity. 
Infusion through hollow μneedles depends on geometry, infusion pressure, 
partial retraction. 
Skin recovery post- μneedle insertion is rapid (within hours) if skin not occluded 
or treated with inhibitors of skin repair. 
Biopharmaceutical drug stability in μneedles. 
Pain on μneedle insertion appears minimal, but transient erythema observed. 
No increased risk of infection at poration site is yet apparent. 
Attractive to patients and healthcare workers. 
aNote that the fabrication methods, mechanism, medical applications and practical issues listed are 
not necessarily specific to one particular microneedle material. 
Concluding comment 
In a little over 30 years, transdermal delivery has been transformed from an interesting new 
idea to a multi-billion US dollar per year industry.  As a controlled release technology, TDD 
has, in many ways, out-performed by some distance most of its “sexier” competitors and 
appears likely to continue to do so in the foreseeable future.  For most of its lifetime, TDD 
has kept to its relatively modest ambitions, recognising its limitations and batting away a 
variety of upstart ideas that showed no respect to the formidable bioengineering of the skin 
barrier.  While forays into more exotic territory, such as iontophoresis, have offered 
seductive promises that have yet to deliver any tangible, economic return, the most recent 
explorations of what might be possible when new openings are made in the skin are now in 
the vanguard of research and future development.  The next 5-10 years will reveal the 
extent to which the TDD landscape may be reconfigured by this work. 
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